Drug Profile
Research programme: imino sugar therapeutics - Summit
Alternative Names: MNLP462a; SMT-14224; SMT-14400; SMT-C2100; VOX 14400Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MNLpharma
- Developer Summit plc; Summit Therapeutics
- Class Imino sugars; Small molecules
- Mechanism of Action Glucose modulators; Haemoglobin modulators; Hepatitis C virus NS3 protein modulators; Hexosaminidase C inhibitors; Immunomodulators; Immunostimulants; Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cancer; Diabetes mellitus; Hepatitis C; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (PO)
- 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs
- 14 Mar 2013 No development reported - Preclinical for Cancer in United Kingdom (PO)